同种异体移植物对烧伤患者构成风险吗?同种异体移植物与HLA致敏
本Meta分析纳入6项研究(同种异体移植物组71例,非异体移植组95例,共166例),评估烧伤患者术后致敏率。同种异体移植物使用后总体致敏率为73%(CI 39%-92%),接受异体移植者致敏风险显著增加(OR 13.14 [95%CI 1.32-131.00])。但亚组分析中,直接比较接受异体移植联合输血与仅输血者,致敏风险未见显著增加(OR 7.68 [95%CI 0.61-95.86])。
要点
- 烧伤患者使用同种异体移植物后总体致敏率为73%(CI 39%-92%)。
- 接受异体移植者致敏风险显著增加(OR 13.14 [95%CI 1.32-131.00])。
- 异体移植联合输血与仅输血相比,致敏风险未见显著增加(OR 7.68 [95%CI 0.61-95.86])。
核心结论
- 同种异体移植物与烧伤患者致敏风险显著增加相关。
- 已接受输血的烧伤患者额外使用异体移植物是否增加致敏风险尚不明确。
- 需进一步研究阐明烧伤人群中致敏的多因素原因,以解释文献中异体移植物和/或输血的贡献意义。
- 临床医生必须仔细权衡异体移植的即时获益与致敏的潜在长期挑战,尤其是在有其他创面治疗选择时。
研究设计与样本
- 系统评价、Meta分析与Meta回归,遵循PRISMA指南,Prospero注册号CRD42024497137。
- 检索MEDLINE、Embase、CENTRAL数据库(通过ProQuest Dialog)。
- 纳入报告烧伤患者术后致敏的研究,排除病例系列或单个病例报告。
- 共纳入6项研究,同种异体移植物组71例,非异体移植组95例,总计166例。
主要发现
- 同种异体移植物使用后烧伤患者总体致敏率为73%(CI 39%-92%)。
- 接受异体移植者致敏风险显著增加(OR 13.14 [95%CI 1.32-131.00])。
- 亚组分析中,异体移植联合输血与仅输血相比,致敏风险未见显著增加(OR 7.68 [95%CI 0.61-95.86])。
临床怎么用
- 临床医生必须仔细权衡异体移植的即时获益与致敏的潜在长期挑战,尤其是在有其他创面治疗选择时。
局限性
- 已接受输血的烧伤患者额外使用异体移植物是否增加致敏风险尚不明确。
- 需进一步研究阐明烧伤人群中致敏的多因素原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This meta-analysis aimed to quantify sensitization rates following allograft usage and determine whether allografts have an increased risk of long-term sensitization compared to alternative therapies in burn patients. METHODS: Systematic review, meta-analysis and meta-regression of post-operative sensitization in burn patients were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidance (Prospero registration: CRD42024497137). Database searches were conducted on MEDLINE, Embase, CENTRAL using ProQuest Dialog. We included all studies reporting post-operative sensitization in burn patients that were not case series or singular case reports. Meta-analysis was used to compare the risk of sensitization for allograft versus alternative therapies. RESULTS: Six studies (Allograft Patients: 71; Non-Allograft Patients: 95) were included (n = 166). Overall, 73 % (CI: 39 %-92 %) of burn patients were sensitized following allograft. Patients receiving allograft were at a significantly increased risk of sensitization (OR 13.14 [95 % CI: 1.32-131.00]). However, on sub-group analysis, when directly comparing patients who received allograft and transfusion versus those who received transfusion alone, there was not a significantly increased risk of sensitization (OR 7.68 [95 % CI:.61-95.86]). CONCLUSION: Allograft is associated with a significantly increased risk of sensitization in burn patients. However, it is not clear whether burn patients already receiving transfusion will have an increased risk of sensitization from adding allograft. Further studies are required to demonstrate the multifactorial causes of sensitization within the burned population to explain the significance of the contribution from allograft and/or transfusion reported within the literature. Clinicians must carefully weigh the immediate benefits of allografts against the potential long-term challenges of sensitization, especially where alternative wound therapies are possible.
引用
- Tsai J, Kim L, Jones I, et al. Do allografts present a risk to burn patients? Allografts and HLA-sensitization. Burns. 2025. PMID: 40121705. doi:10.1016/j.burns.2025.107424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。